SECTION 3
Regulators increasingly require more diverse trials. In this section, we outline why you need to plan your diversity strategy early, discuss our research on barriers to trial participation, explore more equitable reimbursement for research participants, and report on patients' and sites' perceptions of clinical research in China.
Stay current with novel thinking and actionable insights from our experts.
Patient-guided drug development requires more than a 30-minute meeting with patient advocates or aspirational text on a website. It is a systematic approach that begins at the earliest stages of development and informs nearly every decision afterward. Our Office of the Patient helps sponsors make use of patient insights to navigate an increasingly complex reimbursement landscape, mitigate risks, and develop commercially viable products that deliver relevant patient benefits.